We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News and Perspectives |

IOM Urges FDA to Be More Aggressive in Monitoring Safety of Approved Drugs

Bridget M. Kuehn
JAMA. 2012;307(23):2475-2476. doi:10.1001/jama.2012.5993.
Text Size: A A A
Published online


The Institute of Medicine (IOM) has urged the Food and Drug Administration (FDA) to be more proactive in dealing with safety concerns that emerge after a drug is on the market. The recommendation was issued as part of a final report on postmarketing safety from the IOM released in May (http://tinyurl.com/cxovshm).

The FDA requested the report as it considered what actions it should take to curb cardiovascular adverse effects linked with use of the diabetes medication rosiglitazone. The IOM committee charged with drafting the report submitted a brief preliminary version to the FDA during the deliberations in July 2010. Ultimately, the FDA and its European counterpart decided to greatly limit the use of rosiglitazone. In September 2010, the FDA announced changes to the labels on rosiglitazone-containing products to indicate they should be prescribed only to patients currently using the drug or to patients who have been unable to control their blood glucose using other medications and who have been fully informed of the drug's risks (http://tinyurl.com/66gtzq3).

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

A new Institute of Medicine report urges the US Food and Drug Administration to improve its postmarketing surveillance of medications.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles